Ipratropium bromide monohydrate

Research use only, not for human use.

Ipratropium Bromide is a muscarinic antagonist, bronchodilator, N-Isopropyl salt of atropine.

Ipratropium Bromide is a muscarinic antagonist, bronchodilator, N-Isopropyl salt of atropine.(In Vitro):Ipratropium bromide hydrate (1 nM, 10 nM, 100 nM; 15 min) exerts its toxic effects via disruption of mitochondrial membrane potential.Ipratropium bromide hydrate (1 nM-1 μM; 4 h) increases infarct size in isolated perfused heart ischaemia/reperfusion experiments with a dose-responsive manner (EC50=22.7 nM).Ipratropium bromide hydrate (0.001 nM-0.1 mM; 2 h) inhibits adult rat cardiac myocyte growth after 4 h hypoxia treatment.(In Vivo):Ipratropium bromide hydrate (1.0 μg/kg; i.v.; single dose) enhances vagal nerve stimulation induing bronchoconstriction.Ipratropium bromide hydrate (0.04 mg/20 mL and 0.20 mg/20 mL; inhalation for 30 min, rate=30 mL/30 min) can protect the lungs against the cadmium-induced acute neutrophilic inflammation by reducing the parenchyma inflammatory infiltration of neutrophils.

Ipratropium bromide hydrate (1 nM, 10 nM, 100 nM; 15 min) exerts its toxic effects via disruption of mitochondrial membrane potential.Ipratropium bromide hydrate (1 nM-1 μM; 4 h) increases infarct size in isolated perfused heart ischaemia/reperfusion experiments with a dose-responsive manner (EC50=22.7 nM).Ipratropium bromide hydrate (0.001 nM-0.1 mM; 2 h) inhibits adult rat cardiac myocyte growth after 4 h hypoxia treatment. Cell Viability Assay Cell Line:Adult Rat Cardiac Myocyte Concentration:0.001 nM-0.1 mM Incubation Time:2 h in dark; prior to 4 h hypoxia Result:Resulted cell viability in a dose-dependent manner, with the inhibition rate of 52.7% at 0.1 mM dose.

Ipratropium bromide hydrate (1.0 μg/kg; i.v.; single dose) enhances vagal nerve stimulation induing bronchoconstriction.Ipratropium bromide hydrate (0.04 mg/20 mL and 0.20 mg/20 mL; inhalation for 30 min, rate=30 mL/30 min) can protect the lungs against the cadmium-induced acute neutrophilic inflammation by reducing the parenchyma inflammatory infiltration of neutrophils. Animal Model:Guinea-pigs of the Dunkin Hartley strain Dosage:0.1-1 μg/kg Administration:Intravenous injection; single dose Result:Resulted little blocking effect on post-junctional muscarinic receptors at 0.3 μg/kg, and inhibited ACh-induced bronchoconstriction at 0.5 μg/kg.Animal Model:Male Sprague-Dawley rats (300-350 g)Dosage:0.04 mg/20 mL and 0.20 mg/20 mL Administration:Inhalation; atomization rate of 30 mL/30 min; 30 min Result:Had no significant effects on any parameters recorded in healthy rats but exerted a protective effect against the inflammatory reaction elicited by cadmium.

——

Endocrinology/Hormones

AChR

mAChR

Inflammation/Immunology

——

66985-17-9

430.38

C20H32BrNO4

>98% (HPLC)

DMSO, Ethanol and Water: 200 mM

CC(C)[N+]1(C)C2CCC1CC(C2)C(=O)C(CO)C1=CC=CC=C1

——

(-20℃)

With Ice Pack

≥ 2 years